Latest Commercialisation News

Altech Batteries has secured a strategic collaboration with a leading global battery manufacturer to evaluate its breakthrough Silumina Anodes™ silicon-enhanced technology, marking a significant step toward commercialisation.

LaserBond’s 2025 AGM reveals a pivotal CEO transition alongside a strong financial rebound driven by strategic investments and technology licensing deals.

Ava Risk Group announces the upcoming retirement of CEO Mal Maginnis, with senior executive Neville Joyce appointed as Acting CEO. The company embarks on a global search for a permanent replacement amid strong recent growth.

Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.

Independent testing by UNSW confirms Green Critical Minerals’ Very High Density (VHD) technology outperforms copper and aluminium in thermal conductivity and diffusivity, positioning it as a breakthrough in thermal management.

Argosy Minerals has executed a spot sales contract for 16.1 metric tonnes of lithium carbonate from its Rincon project, marking a key commercial milestone amid rising lithium prices.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

I Synergy Group’s subsidiary has inked four separate 12-month leases for its AI computing hardware and software, marking a strategic push into recurring revenue streams.

RocketBoots Limited has successfully converted its AI-powered retail banking trial into a contract rollout with a major Australian bank, marking a significant step in its commercial expansion.

Environmental Clean Technologies is set to convert a $1.13 million convertible note into equity, significantly reducing debt and freeing resources to advance its PFAS remediation technology.

Li-S Energy has accelerated its transition from research to manufacturing with a $7.8 million ARENA grant, new commercial partnerships, and plans for a large-scale production facility.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.